Executive Director and Professor, Tufts University School of Medicine
Assessing Practices & Inefficiencies with Site Selection, Study Start-Up, and Site Activation
August 5th 2016Study finds that despite the use of new approaches to streamline and accelerate study start and improve site selection and activation, the impact on start-up cycle times has been limited. The reasons why are explored.
Closing in on Opportunities to Simplify Protocol Design
February 1st 2015Sponsor companies face intense pressure to deliver higher levels of efficiency and drug development performance. A growing number of sponsors are now acting on the belief that improvements in protocol design feasibility hold the key to addressing and easing some of these pressures.